These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 28462395)
1. Calmodulin and PI3K Signaling in Nussinov R; Wang G; Tsai CJ; Jang H; Lu S; Banerjee A; Zhang J; Gaponenko V Trends Cancer; 2017 Mar; 3(3):214-224. PubMed ID: 28462395 [TBL] [Abstract][Full Text] [Related]
2. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers. Nussinov R; Zhang M; Tsai CJ; Jang H Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261 [TBL] [Abstract][Full Text] [Related]
3. Flexible-body motions of calmodulin and the farnesylated hypervariable region yield a high-affinity interaction enabling K-Ras4B membrane extraction. Jang H; Banerjee A; Chavan T; Gaponenko V; Nussinov R J Biol Chem; 2017 Jul; 292(30):12544-12559. PubMed ID: 28623230 [TBL] [Abstract][Full Text] [Related]
4. Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH Zhang M; Jang H; Gaponenko V; Nussinov R Biophys J; 2017 Nov; 113(9):1956-1967. PubMed ID: 29117520 [TBL] [Abstract][Full Text] [Related]
5. The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O Mol Cancer Res; 2015 Sep; 13(9):1265-73. PubMed ID: 26085527 [TBL] [Abstract][Full Text] [Related]
6. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant? Nussinov R; Tsai CJ; Jang H Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569 [TBL] [Abstract][Full Text] [Related]
7. Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit. Wang G; Zhang M; Jang H; Lu S; Lin S; Chen G; Nussinov R; Zhang J; Gaponenko V Biochemistry; 2018 Mar; 57(12):1917-1928. PubMed ID: 29494137 [TBL] [Abstract][Full Text] [Related]
8. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target? Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344 [TBL] [Abstract][Full Text] [Related]
9. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α. Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727 [TBL] [Abstract][Full Text] [Related]
10. The dynamic nature of the K-Ras/calmodulin complex can be altered by oncogenic mutations. Abdelkarim H; Leschinsky N; Jang H; Banerjee A; Nussinov R; Gaponenko V Curr Opin Struct Biol; 2021 Dec; 71():164-170. PubMed ID: 34311289 [TBL] [Abstract][Full Text] [Related]
11. The Structural Basis of the Farnesylated and Methylated KRas4B Interaction with Calmodulin. Jang H; Banerjee A; Marcus K; Makowski L; Mattos C; Gaponenko V; Nussinov R Structure; 2019 Nov; 27(11):1647-1659.e4. PubMed ID: 31495533 [TBL] [Abstract][Full Text] [Related]
12. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin. Ni D; Liu D; Zhang J; Lu S Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353 [TBL] [Abstract][Full Text] [Related]
13. Both the C-terminal polylysine region and the farnesylation of K-RasB are important for its specific interaction with calmodulin. Wu LJ; Xu LR; Liao JM; Chen J; Liang Y PLoS One; 2011; 6(7):e21929. PubMed ID: 21750741 [TBL] [Abstract][Full Text] [Related]
14. v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Akagi T; Murata K; Shishido T; Hanafusa H Mol Cell Biol; 2002 Oct; 22(20):7015-23. PubMed ID: 12242282 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic Ras Isoforms Signaling Specificity at the Membrane. Nussinov R; Tsai CJ; Jang H Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632 [TBL] [Abstract][Full Text] [Related]
16. Loss of Cbl-PI3K interaction enhances osteoclast survival due to p21-Ras mediated PI3K activation independent of Cbl-b. Adapala NS; Barbe MF; Tsygankov AY; Lorenzo JA; Sanjay A J Cell Biochem; 2014 Jul; 115(7):1277-89. PubMed ID: 24470255 [TBL] [Abstract][Full Text] [Related]
17. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B. Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384 [TBL] [Abstract][Full Text] [Related]
18. The hypervariable region of K-Ras4B is responsible for its specific interactions with calmodulin. Abraham SJ; Nolet RP; Calvert RJ; Anderson LM; Gaponenko V Biochemistry; 2009 Aug; 48(32):7575-83. PubMed ID: 19583261 [TBL] [Abstract][Full Text] [Related]
19. The structural basis of Akt PH domain interaction with calmodulin. Weako J; Jang H; Keskin O; Nussinov R; Gursoy A Biophys J; 2021 May; 120(10):1994-2008. PubMed ID: 33775637 [TBL] [Abstract][Full Text] [Related]
20. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Alvarez-Moya B; López-Alcalá C; Drosten M; Bachs O; Agell N Oncogene; 2010 Nov; 29(44):5911-22. PubMed ID: 20802526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]